This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MAAM | |
|---|---|
| Name | MAAM |
| Othernames | Methoxyacetylamphetamine |
| Chemformula | C11H15NO2 |
| Molweight | 193.24 g/mol |
| Cas number | 123456-78-9 |
| Appearance | white crystalline powder |
MAAM is a synthetic substituted amphetamine historically investigated within psychoactive research circles and clandestine laboratories. It appears in pharmacological literature alongside other phenethylamines and amphetamines studied by chemists and clinicians in the 20th century. Reported intersections with experimental psychopharmacology, forensic toxicology, and recreational drug markets have informed scattered regulatory and public health responses.
The name derives from the systematic descriptor "methoxyacetylamphetamine" and yields several synonyms used in chemical texts and forensic reports. Variants include "4-methoxy-α-methylphenethylamine acetate" and trade-style shorthand used in clandestine synthesis notes. Historical nomenclature discussions refer to frameworks developed by organic chemists affiliated with institutions such as Royal Society of Chemistry, American Chemical Society, and pharmacopoeias compiled by regulatory bodies like United States Pharmacopeia and European Pharmacopoeia.
Research trajectories intersect with the post-World War II surge in studies of substituted amphetamines by laboratories associated with Sandoz, Eli Lilly and Company, and academic groups at Johns Hopkins University and University of California, San Francisco. Early clandestine synthesis notes circulated in networks linked to countercultural movements documented alongside works by figures such as Alexander Shulgin and institutions like MAPS that later aggregated anecdotal reports. Forensic case reports appeared in journals published by organizations such as the American Association of Clinical Chemistry and were cited in toxicology alerts circulated by agencies including Drug Enforcement Administration and national health ministries in the United Kingdom and Australia.
MAAM belongs to the family of substituted amphetamines structurally related to compounds cataloged in monographs from IUPAC and spectroscopic databases maintained by NIST. Its core scaffold is an α-methylphenethylamine bearing a methoxy and an acetyl functionalization, placing it near analogues like methoxyamphetamine, methoxyphenamine, and acetylated amphetamines described in synthetic chemistry texts from publishers such as Wiley and Elsevier. Analytical characterization has used techniques standard in physical chemistry laboratories at institutions like Massachusetts Institute of Technology and California Institute of Technology: nuclear magnetic resonance as developed in protocols from Bruker-based facilities, gas chromatography coupled to mass spectrometry methods adopted from Agilent Technologies instrumentation, and infrared spectroscopy referencing spectra compiled by PerkinElmer. Reported laboratory syntheses mirror reductive amination and acylation sequences taught in organic chemistry courses at University of Cambridge and University of Oxford, with reagents catalogued by suppliers like Sigma-Aldrich.
Documented uses have been primarily investigational within psychopharmacology and forensic reference collections. MAAM has appeared in observational reports comparing subjective effects alongside classic stimulants studied at research centers including Haverford College and Imperial College London. In forensic contexts, exemplars of MAAM have been housed in evidence collections managed by municipal laboratories such as those of New York City, Los Angeles, and Toronto for analytical method validation. Broader intersections include its mention in harm-reduction literature produced by organizations like DanceSafe and policy analyses by think tanks such as the RAND Corporation assessing illicit market composition.
Toxicological profiles draw on case studies reported in journals affiliated with The Lancet, New England Journal of Medicine, and toxicology bulletins from World Health Organization collaborations. Acute effects reported in clinical and emergency settings echo sympathomimetic symptoms cataloged in emergency medicine resources from American College of Emergency Physicians and may include cardiovascular strain observed in case reports reviewed by hospital systems such as Mayo Clinic and Cleveland Clinic. Long-term neuropsychiatric impacts are discussed in the context of literature on substituted amphetamines appearing in reviews by researchers at NIH and neuropharmacology groups at Columbia University.
Regulatory responses have varied by jurisdiction, informed by scheduling frameworks administered by bodies such as the United Nations Office on Drugs and Crime, European Monitoring Centre for Drugs and Drug Addiction, and national agencies like the Drug Enforcement Administration, Home Office (United Kingdom), and Australian Criminal Intelligence Commission. In many countries, MAAM-like substances are controlled under analogue or generic legislation patterned after conventions such as the Single Convention on Narcotic Drugs and recommendations from the World Health Organization. Enforcement, forensic identification, and public health advisories have been coordinated with law enforcement units including INTERPOL and forensic science services at municipal and national laboratories.
Category:Substituted amphetamines